US regulator stops leukemia treatment trial after three patients dieBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3893 (Published 14 July 2016) Cite this as: BMJ 2016;354:i3893
- Nigel Hawkes
A trial of a promising immunological treatment for leukemia has been stopped by the US Food and Drug Administration (FDA) after three patients died.
The treatment for acute lymphocytic leukemia involved engineering T cells taken from a patient’s blood so that they recognized specific antigens on the surface of tumor cells. The modified T cells were grown in a laboratory and were reintroduced into the patient to attack and destroy the tumor.
The engineering process made the T cells produce …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial